Delivery Order SPE2DB24D3013-SPE2DB25FFQHV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,326.27 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injectors. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant medication used primarily to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $5,755.68 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 MG/0.9 ML auto-injectors. This non-set-aside, firm fixed price delivery order was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra ActPen (162 mg/0.9 mL) auto-injectors. This firm fixed price delivery order carries a ceiling value of $3,066.26 and is scheduled for completion by August 19, 2025. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements....
- The Defense Logistics Agency awarded a delivery order valued at $38,677.92 to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.94 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,066.95 by the Defense Logistics Agency (DLA) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. The contract covers the supply of Actemra ActPen 162 mg/0.9 mL injections and was awarded through competitive bidding without set-aside designation under a firm fixed-price arrangement. This delivery order operates as a child...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQHVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, representing a specialized pharmaceutical product within the company's broader federal medical supply portfolio. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999 and extending through December 2026. This prime vendor agreement provides comprehensive pharmaceutical support to military healthcare systems and the Defense Health Agency. AmerisourceBergen's award demonstrates its capacity to supply specialized biologic medications alongside its extensive portfolio of brand-name and generic drugs, vaccines, and medical devices that support federal military and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/9/25 |